Approval · Notice of Compliance 26327 · 2021
LEQVIO: Notice of Compliance 26327
Issued July 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26327
- Date
- July 26, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEQVIO | 02518376 | Marketed |
Medicinal ingredients
- INCLISIRAN SODIUM 284 MG per 1.5ML